Baseline demographics and clinical characteristics
| Demographics | |
| Number of patients | 117 |
| Weight, kg | |
| Mean (SD) | 69.8 (18.8) |
| Gender, n (%) | |
| Female | 85 (72.6) |
| Male | 32 (27.4) |
| Diagnosis, n (%) | |
| Ulcerative colitis | 16 (13.7) |
| Crohn’s disease | 35 (29.9) |
| Non-IBD disorders | 66 (56.4) |
| Disease medication, n (%) | |
| Cortisone | 1 (0.9) |
| Mesalazine | 14 (12.0) |
| Thiopurine | 10 (8.5) |
| Biological treatment | 38 (32.5) |
| Previously prescribed oral iron, n (%) | 34 (29.1) |
| Intolerant of oral iron, n (%) | 14 (41.2) |
| Unresponsive to oral iron, n (%) | 5 (14.7) |
| No data for response to oral iron, n (%) | 15 (44.1) |
| Clinical characteristics | |
| Hb, g/L (n) | 114 |
| Mean (SD) | 101.6 (15.4) |
| Anaemia status,* n | 114 |
| Anaemic, n (%) | 108 (94.7) |
| Non-anaemic, n (%) | 6 (5.3) |
| Ferritin, μg/L (n) | 75 |
| Mean (SD) | 26.6 (37.8) |
| Median (range) | 12 (2–174) |
*Anaemia was defined as Hb <130 g/L (males) or <120 g/L (females)
Hb, haemoglobin; IBD, inflammatory bowel disease.